Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2020;70:7–30.
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66:7–30.
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics. CA Cancer J Clin. 2017;67:177-93.
Schepisi G, Farolfi A, Conteduca V, Martignano F, De Lisi D, Ravaglia G, et al. Immunotherapy for prostate cancer: where are we headed? Int J Mol Sci. 2017;18:2627.
Drake CG. Prostate cancer as a model for tumor immunotherapy. Nat Rev Immunol. 2010;10:580–93.
Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, et al. VISTA is an inhibitory immune checkpoint that increases after ipilimumab treatment in prostate cancer patients. Nat Med. 2017;23:551–5.
Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Phase III, randomized, double-blind trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with chemotherapy-naive metastatic castration-resistant prostate cancer. J Clin Oncol. 2017;35:40–47.
Hansen AR, Massard C, Haas NB, Lopez JS, Ejadi S, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: results of the KEYNOTE-028 study. Ann Oncol. 2018;29:1807–13.
Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: drive T cells to solid tumors. Cancer Discov. 2016;6:133–46.
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139.
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17.
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. rev. 2018;378:439–48.
Park JH, Rivière I, Gonen M, Wang X, Senéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Son Ö, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545–54.
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR bb2121 T-cell therapy in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–37.
Di S, Li Z. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects. Science Life China Science. 2016;59:360–9.
Mirzaei HR, Rodriguez A, Shepphird J, Brown CE, Badie B. Chimeric antigen receptors T-cell therapy in solid tumor: challenges and clinical applications. Front Immunol. 2017;8:1850.
Li J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q. Chimeric antigen receptor T-cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol. 2018; 11:22.
Flem-Karlsen K, Fodstad Ø, Tan M, Nunes-Xavier CE. B7-H3 in cancer: beyond immune regulation. Cancer trends. 2018;4:401–4.
Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 2016;22:3425–31.
Tekle C, Nygren MK, Chen YW, Dybsjord I, Nesland JM, Maelandsmo GM, et al. B7-H3 contributes to the metastatic capacity of melanoma cells by modulating known metastasis-associated genes. Int J Cancer. 2012;130:2282–90.
Castellanos JR, Purvis I, J Labak CM, Guda MR, Tsung AJ, Velpula KK, et al. Role of B7-H3 in the immune landscape of cancer. Am J Clin Exp Immunol. 2017;6:66–75.
Ye Z, Zheng Z, Li X, Zhu Y, Zhong Z, Peng L, et al. B7-H3 overexpression predicts poor survival of cancer patients: a meta-analysis. Cell Physiol Biochem. 2016;39:1568–80.
Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P, et al. Compartmental intrathecal radioimmunotherapy: results for the treatment of metastatic CNS neuroblastoma. J Neurooncol. 2010;97:409–18.
Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012;18:3834–45.
Powderly J, Cote G, Flaherty K, Szmulewitz RZ, Ribas A, Weber J, et al. Interim results of an ongoing phase I dose-escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7- H3. J Cancer Immunotherapy. 2015;3:O8.
Souweidane M, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P, et al. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-dose escalation phase 1 trial. Lancet Oncol. 2018;19:1040–50.
Modak S, Carrasquillo J, Laquaglia M, Pat Z, Pandit-Taskar N. Abstract CT006: intraperitoneal radioimmunotherapy for desmoplastic small round cell tumor: results of a phase I study (NCT01099644). Cancer Res. 2018;78:CT006–CT006.
Yang S, Wei W, Zhao Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci. 2020;16:1767–73.
Nehama D, Di Ianni N, Musio S, Du H, Patane M, Pollo B, et al. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicina. rev. 2019;47:33–4
Zhang Z, Jiang C, Liu Z, Yang M, Tang X, Wang Y, et al. B7-H3-targeted CAR-T cells exhibit potent antitumor effects on hematological and solid tumors. Mol Ther Oncolytics. 2020;17:180–9.
Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer cell. 2019;35:221–37.
Newick K, O’Brien S, Moon E, Albelda SM. CAR T-cell therapy for solid tumors. Annu Rev Med. 2017;68:139–52.
Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Dis. 2017;20:28–35.
Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P, et al. Compartmental intrathecal radioimmunotherapy: results for the treatment of metastatic CNS neuroblastoma. J Neurooncol. 2010;97:409–18.
Kramer K, Smith M, Souweidane MM. Long-term safety profile of intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignancies. Pediatrician Blood cancer. 2014;61:1590–2.
Liu Z, Zhang W, Phillips JB, Arora R, McClellan S, Li J, et al. Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation. oncogene 2019;38:88–102.
